Insulet Must Show Its Type 2 Retention Problem Is Contained After Guidance Cut

Three months ago, Insulet told investors something they had not heard from the company in a long time: its US growth engine was sputtering. Type 2 patients were starting on Omnipod in record numbers but were not sticking with it or using it as heavily as planned. That forced a cut to full-year revenue guidance and a retreat from the long-range promise of sustained 20%-plus growth. The stock has since rallied hard off its lows, which makes the third-quarter report, due before the open on November 4, less about whether Insulet can grow and more about whether the damage was fully captured in the reset.

The Street is looking for adjusted earnings of $1.59 a share on revenue of $833.3 million, implying growth of roughly 28% and 18%, respectively, from the year-ago quarter. That is still a robust pace for a company of this size, but the revenue figure marks another step down from 23% constant-currency growth in the second quarter and 30% in the first. The earnings whisper of $1.66 sits modestly above consensus and matches last quarter's result, suggesting some investors expect margins to cushion any top-line softness. Management's third-quarter revenue range of about $830 million to $844 million puts consensus in the lower half, a cautious positioning that leaves room for a beat but also signals limited faith in an upside surprise.

The central question is US Omnipod. Management cut its full-year US growth target to 17% to 19% from 20% to 22%, attributing roughly two-thirds of the reduction to weaker retention and utilization assumptions and the rest to slower new customer starts and slightly lower pricing. Validation would look like US growth landing comfortably within that range, along with commentary that the first 90 days of Type 2 onboarding are improving. The company has restructured sales compensation to reward long-term retention rather than simple starts and is leaning on its Omnipod Discover data platform, which showed early retention benefits. Importantly, management said none of those remediation efforts were baked into guidance. Any sign that they are already working would be the most constructive takeaway. Conversely, a further step down in US growth, or vague talk about retention trends, would suggest the problem is deeper than an execution gap.

International and profitability are the supporting acts. International growth guidance was lifted to 30% to 32% in constant currency, helped by Omnipod 5 becoming the top pump for new users in Australia and a launch in Spain. Adjusted gross margin reached 72.9% last quarter, and full-year earnings growth guidance was raised to at least 30%. Continued margin expansion would reinforce that Insulet can deliver earnings even as revenue growth normalizes, though the market will be wary of leaning too heavily on that if free cash flow, now expected to decline modestly, keeps slipping.

Expectations have warmed noticeably. Sentiment remains bearish but less so than heading into the last report, and the shares have gained about 17% since then while the S&P 500 slipped 1.4%. Even so, at roughly $149 the stock remains well below its 200-day moving average near $182 and a few percent shy of its post-earnings high of $155, so the rebound looks more like relief than renewed conviction.

Ultimately, this report is a credibility test. Management deferred formal 2027 guidance to the fourth-quarter call and floated a preliminary mid-teens exit rate, with competitive patch pump entry on the horizon. If the third quarter shows Type 2 retention stabilizing and US growth holding inside the lowered range, the reset will look like a one-time recalibration. If not, investors may conclude the long-range story needs more than a trim.

This earnings preview was originally published on Earnings Whispers.

This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It is AI-assisted, based on proprietary Earnings Whispers data and company reports, and edited by Earnings Whispers staff.